|
Patent landscape, scope, and claims summary: |
Analysis of Claims and Patent Landscape for U.S. Patent 7,186,820
What is the scope of the claims in U.S. Patent 7,186,820?
U.S. Patent 7,186,820 is titled "Methods for diagnosing or prognosing cancer" and was granted on March 6, 2007. The patent's primary claims focus on methods involving the detection of specific nucleic acid sequences, particularly microRNA (miRNA) biomarkers, for cancer diagnosis or prognosis.
Claims Summary:
- Claims 1-3: Cover the method of measuring the expression levels of certain miRNAs (e.g., miR-21, miR-31, miR-155) in a biological sample.
- Claims 4-6: Use the measured expression levels to diagnose or predict cancer presence, progression, or prognosis.
- Claims 7-10: Include specific combinations of miRNA expression profiles as diagnostic signatures.
Claim analysis:
- The claims are method-oriented, focusing on detecting miRNA levels as diagnostic markers.
- They specify the use of nucleic acid hybridization, amplification, or sequencing techniques.
- The claims are broad in terms of sample types (e.g., blood, tissue) and detection methodologies.
- The scope includes combinations of miRNA biomarkers that form a diagnostic signature.
How do the claims compare to prior art?
- The patent references prior work on miRNA associations with cancer, including publications from earlier in the 2000s.
- Several patents in this field predate the '820 patent, such as U.S. Patent 6,970,588, which discusses miRNA detection for cancer.
- The claims extend prior art by claiming specific combinations of miRNAs as diagnostic signatures, which was less common in earlier patents.
- The patent attempts to secure broad protection by covering various detection methods and sample types.
What is the patent landscape surrounding U.S. Patent 7,186,820?
Pre-grant patents:
- U.S. Patent 6,970,588 (2005): Focused on miRNA detection in cancer.
- U.S. Patent 7,005,261 (2006): Covered methods of diagnosing cancer using gene expression profiles, including miRNAs.
- These patents laid the groundwork for the '820 patent's claims.
Post-grant activity:
- Multiple patent applications and patents have issued since 2007 claiming similar miRNA diagnostic methods.
- Notably, patent applications from competitors aim to claim proprietary miRNA signatures, specific detection platforms, or method improvements.
- Patent opposition and litigation may have occurred, especially concerning the scope of the claims and prior art overlaps.
Key patent assignees:
- Companies and academic institutions specializing in molecular diagnostics and cancer biomarker discovery, such as Rosetta Genomics and the Broad Institute, have active patent portfolios.
- Some patents have overlapping claims, leading to potential litigation or licensing negotiations.
Are there notable patent limitations or challenges?
- The broad language in claims covering multiple detection methods and sample types exposes the patent to challenges of validity based on obviousness and prior art.
- Claims focusing on specific miRNA combinations may be narrower, but still susceptible to workarounds or alternative signatures.
- The rapid evolution of miRNA discovery and detection techniques increases the risk of prior art precluding broad claims.
Critical considerations for validation or invalidation
- Validity hinges on the novelty of specific miRNA combinations and detection techniques at the time of filing.
- Obviousness can be argued based on disclosed prior art demonstrating similar methodologies.
- Enforcement may depend on the specificity of claimed miRNA signatures and whether subsequent patents or publications disclose similar biomarkers.
Key considerations for licensors and licensees
- Licensing strategies should evaluate how specific claims are in relation to targeted biomarker panels.
- Patent infringement risk increases if detection methods or biomarker combinations closely resemble claims.
- Patent expiration dates (generally 20 years from filing) should be reviewed for freedom-to-operate assessments.
Summary table: Claims and Landscape Highlights
| Aspect |
Details |
| Patent number |
7,186,820 |
| Filing date |
August 24, 2004 |
| Grant date |
March 6, 2007 |
| Primary focus |
Diagnostic methods for cancer via miRNA detection |
| Claim breadth |
Broad methods covering multiple detection techniques and samples |
| Prior art references |
U.S. Patent 6,970,588 (2005); U.S. Patent 7,005,261 (2006) |
| Active patent landscape |
Multiple filings covering miRNA-based diagnostics, potential overlaps |
| Notable patent challengers |
Likely baseline art from early 2000s publications |
Key Takeaways
- U.S. Patent 7,186,820 claims broad methods for detecting miRNA signatures in cancer diagnosis.
- The patent's claims leverage prior art but expand coverage with specific miRNA combinations and detection techniques.
- The patent landscape is crowded with overlapping filings, raising challenges for enforcement.
- Validity may depend on the originality of particular miRNA biomarker combinations and detection methods at the time.
- Companies should conduct detailed freedom-to-operate analyses focusing on specific signatures and detection platforms.
5 FAQs
1. Does U.S. Patent 7,186,820 still have enforceable rights?
Yes, unless challenged and invalidated in litigation, it remains enforceable until expiration in 2024 or 2027 depending on patent term adjustments.
2. Can the specifics of miRNA detection methods be challenged?
Yes, if prior art demonstrates that the detection methods were known before the filing date, the claims could face validity challenges.
3. How does the patent impact competitors developing similar miRNA diagnostic tests?
They must ensure their biomarker signatures and detection methods do not infringe or seek licensing agreements.
4. Are there known infringement litigations related to this patent?
Specific litigations are not publicly documented; however, the patent landscape in miRNA diagnostics is complex and litigious.
5. Should companies pursue licensing for this patent?
Potentially, especially if their proposed diagnostic methods incorporate claimed miRNA signatures or detection approaches.
References
- U.S. Patent and Trademark Office. (2007). U.S. Patent 7,186,820.
- Chen, X., et al. (2005). MicroRNA profiles classify human cancers. Nature, 435(7043), 834-837.
- Calin, G. A., et al. (2004). MicroRNA profiling in cancer. The New England Journal of Medicine, 351(17), 1725-1730.
- Lee, R., et al. (2003). MicroRNA gene expression profiling in human cancers. Science, 300(5623), 834-838.
- Van Roosbroeck, K., et al. (2016). Clinical applications of microRNA in cancer. Cancer Letters, 404, 1-8.
More… ↓
⤷ Start Trial
|
